ArticleScientific reports2025
NF-κB/ICAM-1 signaling regulates vascular dysfunction in depressive hypertension rats.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The relationship between depression and hypertension has garnered increasing scholarly attention, particularly regarding the role of depression in exacerbating organ damage in hypertensive individuals. Inflammation is a key characteristic of organ damage associated with elevated blood pressure. However, the specific impact of inflammation on vascular dysfunction in hypertensive rats with depression has yet to be fully understood. This study examines the effects of the NF-κB inhibitor MG132 on blood pressure, depression-like behaviors, endothelial function, and vascular remodeling in hypertensive rats exhibiting depressive symptoms. The administration of MG132 resulted in a significant reduction in blood pressure and an improvement in depressive behaviors among these rats. Furthermore, MG132 treatment led to a notable decrease in serum levels of Angiotensin II (AngⅡ) and Vascular Endothelial Growth Factor (VEGF), while increasing nitric oxide (NO) levels in spontaneously hypertensive rats (SHR) and those with chronic depression. Additionally, MG132 inhibited the differentiation of endothelial progenitor cells (EPCs) into smooth muscle cells (SMCs) and reduced the levels of inflammatory cytokines, including high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β). Moreover, MG132 effectively suppressed the expression of NF-κB P65 and its downstream signaling pathway, intercellular adhesion molecule-1 (ICAM-1).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.